For PV patients with JAK2V617F ( + ) , IFN had no OHR superiority to HU ( 70.3 % versus 70.8 % , P > 0.05 ) , but which gained a greater satisfactory molecular response than HU ( 54.7 % versus 19.4 % , P < 0.01 ) .